Vor Biopharma Sees Unusually Large Options Volume (NYSE:VOR)

Vor Biopharma Inc. (NYSE:VOR - Get Free Report) was the target of unusually large options trading on Tuesday. Traders bought 17,569 put options on the company. This represents an increase of approximately 345% compared to the typical daily volume of 3,949 put options.

Analysts Set New Price Targets

A number of analysts have recently commented on the company. Wedbush reiterated an "outperform" rating on shares of Vor Biopharma in a research report on Thursday, June 26th. Stifel Nicolaus cut their target price on Vor Biopharma from $12.00 to $5.00 and set a "buy" rating on the stock in a research report on Friday, March 21st. Jones Trading cut Vor Biopharma from a "strong-buy" rating to a "hold" rating in a research report on Thursday, May 8th. Baird R W cut Vor Biopharma from a "strong-buy" rating to a "hold" rating in a research report on Thursday, May 8th. Finally, JMP Securities reissued a "market perform" rating and set a $6.00 price target on shares of Vor Biopharma in a report on Friday, May 9th. Four investment analysts have rated the stock with a hold rating and six have given a buy rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and an average target price of $5.63.

Hedge Funds Weigh In On Vor Biopharma

A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. RA Capital Management L.P. grew its holdings in shares of Vor Biopharma by 74.3% during the fourth quarter. RA Capital Management L.P. now owns 39,646,039 shares of the company's stock worth $44,007,000 after buying an additional 16,897,159 shares during the last quarter. Lynx1 Capital Management LP purchased a new stake in Vor Biopharma in the 4th quarter valued at approximately $707,000. Jane Street Group LLC purchased a new stake in Vor Biopharma in the 1st quarter valued at approximately $140,000. Two Sigma Investments LP boosted its holdings in Vor Biopharma by 18.9% in the 4th quarter. Two Sigma Investments LP now owns 163,064 shares of the company's stock valued at $181,000 after purchasing an additional 25,930 shares in the last quarter. Finally, Northern Trust Corp boosted its holdings in Vor Biopharma by 39.0% in the 4th quarter. Northern Trust Corp now owns 157,617 shares of the company's stock valued at $175,000 after purchasing an additional 44,252 shares in the last quarter. Hedge funds and other institutional investors own 97.29% of the company's stock.

Vor Biopharma Trading Up 8.2%

Shares of NYSE VOR traded up $0.19 during midday trading on Friday, reaching $2.50. 15,990,279 shares of the company were exchanged, compared to its average volume of 4,740,701. Vor Biopharma has a 1 year low of $0.13 and a 1 year high of $3.29. The stock has a fifty day simple moving average of $0.64 and a 200 day simple moving average of $0.91. The stock has a market cap of $312.40 million, a P/E ratio of -1.52 and a beta of 2.04.

Vor Biopharma Company Profile

Vor Biopharma Inc operates as a clinical-stage cell and genome engineering company. Its lead product is tremtelectogene empogeditemcel (trem-cel), an engineered hematopoietic stem cell (eHSC) product candidate that is in phase 1/2 trial to treat acute myeloid leukemia (AML) and other hematological malignancies.